Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206219 · ClinicalTrials.gov registry record · Phase 3
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 477
- Enrollment target
NCT00206219 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 477 participants.
The verdict
NCT00206219, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 477 participants
- Enrollment target
Study Summary
This study is to compare ZD1839 (250mg and 500mg) versus methotrexate in head and neck cancer in terms of overall survival.
Interventions
- DRUG Gefitinib
- DRUG methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 477 participants |
| Start Date | 2003-11 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206219
The ClinicalTrials.gov registry entry for NCT00206219 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 477 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gefitinib is the first listed.
NCT00206219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206219 about?
NCT00206219 is a clinical study titled "Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)". This study is to compare ZD1839 (250mg and 500mg) versus methotrexate in head and neck cancer in terms of overall survival.
What is the current status of trial NCT00206219?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 477 participants. The study started on 2003-11. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00206219?
The interventions under investigation include: Gefitinib (DRUG), methotrexate (DRUG).
Who is sponsoring clinical trial NCT00206219?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.